|1.||Jia, Chi-Yu: 1 article (04/2009)|
|2.||Scanlon, Ian: 1 article (03/2002)|
|3.||Niculescu-Duvaz, Ion: 1 article (03/2002)|
|4.||Friedlos, Frank: 1 article (03/2002)|
|5.||Davies, Lawrence: 1 article (03/2002)|
|6.||Spooner, Robert A: 1 article (03/2002)|
|7.||Ogilvie, Lesley M: 1 article (03/2002)|
|8.||Stribbling, Stephen M: 1 article (03/2002)|
|9.||Martin, Janet: 1 article (03/2002)|
|10.||Marais, Richard: 1 article (03/2002)|
12/01/1997 - "Systemic administration of CMDA to mice bearing established xenografts of the transfected cells led to sustained tumor regressions or cures."
01/01/1994 - "An antibody-carboxypeptidase G2 (CPG2) enzyme is delivered prior to the nontoxic prodrug, CMDA, which is converted to a cytotoxic drug by the action of the localized conjugate at the tumor site. "
03/15/2002 - "All three of the prodrugs produced histological evidence of substantial bystander cell killing in WiDr xenografts in which only 10% or 50% of the cells inoculated were expressing stCPG2(Q)3. We conclude that all three of the prodrugs are more effective therapeutically with stCPG2(Q)3 than is the previously described prodrug CMDA and, also, that the optimal choice of prodrug varies among different tumor types and that prodrugs, optimized for their bystander effect, are effective when only low percentages of cells in a tumor express CPG2."
04/01/2001 - "The most widely used enzyme/prodrug combinations already in clinical trials (e.g., herpes simplex 1 virus thymidine kinase/ganciclovir and cytosine deaminase/5-fluorocytosine), as well as novel approaches (carboxypeptidase G2/CMDA, horseradish peroxidase/indole-3-acetic acid) are described, with a particular attention to translational research and early clinical results."
12/01/1997 - "Breast carcinoma MDA MB 361 cells expressing CPG2 internally showed only a very modest increase in sensitivity to the prodrug CMDA because the prodrug did not enter the cells. "
01/20/2000 - "The role of the bystander effect in the treatment of a human breast carcinoma xenograft was studied by suicide gene therapy with carboxypeptidase G2 (CPG2) and CMDA. "
01/20/2000 - "Regressions of established breast carcinoma xenografts by carboxypeptidase G2 suicide gene therapy and the prodrug CMDA are due to a bystander effect."
03/15/2002 - "All three of the prodrugs produce much greater cytotoxicity differentials between stCPG2(Q)3- and control beta-galactosidase (beta-gal)-expressing breast carcinoma MDA MB 361 and colon carcinoma WiDr cells (70- to 450-fold) than was previously observed (19- to 27-fold) with 4-[(2-chloroethyl)(2-mesyloxyethyl)amino]benzoyl-L-glutamic acid (CMDA). "
|2.||gamma-Glutamyl Hydrolase (Carboxypeptidase G2)
|4.||Acetic Acid (Vinegar)
|9.||Glutamic Acid (Glutamate)
|1.||Heterologous Transplantation (Xenotransplantation)